Anavex Life Sciences Completes Clinical Conduct Of Drug-Drug Interaction, Absorption, Distribution, Metabolism And Excretion Trials Of Blarcamesine; Receives FDA Clearance For Its Investigational New Drug Application In Fragile X Syndrome; To Meet With FDA To Discuss Inclusion Of Participants In Its Phase 3 Rett Syndrome Trial